Señales en vivo de TERN | Maximiza tus Ganancias con Getagraph.com

VENDER 106797 min ago

@ $6.86

Emitido: 14 feb 2024 @ 09:30

Retorno: -28.43%

Señal anterior: feb 9 - 15:54

Señal anterior: Comprar

Retorno: -0.72 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	495 961
Volumen promedio	896 139
Capitalización de mercado	317.44M
EPS	$0 ( 2024-03-25 )
Próxima fecha de ganancias	( $-0.360 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.87
ATR14	$0.00900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Vivo Opportunity, Llc	Sell	136 255	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	76 346	Common Stock
2024-04-03	Vivo Opportunity, Llc	Sell	103 870	Common Stock
2024-04-01	Vivo Opportunity, Llc	Sell	39 411	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	22 084	Common Stock

INSIDER POWER
68.20
Last 96 transactions
Buy: 25 215 859 \| Sell: 2 318 163

Volumen Correlación

Largo: 0.60 (weak)

Corto: -0.48 (neutral)

Signal:(69.062) Neutral

Terns Pharmaceuticals, Correlación

10 Correlaciones Más Positivas
SVAC	0.926
EMLD	0.908
ARTEU	0.905
CFFE	0.905
PAIC	0.898
LRMR	0.898
GDST	0.897
ARIZ	0.896
CARG	0.892
LQDA	0.891

10 Correlaciones Más Negativas
BCAB	-0.929
ATAI	-0.923
CUTR	-0.923
SMFL	-0.92
GMAB	-0.919
MYSZ	-0.919
SRAC	-0.916
SPCX	-0.908
VFF	-0.906
NCBS	-0.903

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Terns Pharmaceuticals, Correlación - Moneda/Commodity

-0.10
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.14
( neutral )

-0.41
( neutral )

Terns Pharmaceuticals, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.03M (0.00 %)
EPS:	$-1.670

FY	2021
Ingresos:	$1.00M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.21

Financial Reports:

No articles found.

Terns Pharmaceuticals,

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.